ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO873

Long-Term Outcomes of Rituximab Treatment in Membranous Nephropathy

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Nikolopoulou, Aikaterini K., Imperial College London, London, United Kingdom
  • Teixeira, Ana Catarina, Coimbra Hospital and Universitary Centre, Coimbra, Portugal
  • McAdoo, Stephen Paul, Imperial College London, London, United Kingdom
  • Levy, Jeremy B., Imperial College Healthcare NHS Trust, London, United Kingdom
  • Tam, Frederick W.K., Imperial College Kidney and Transplant Institute, London, United Kingdom
  • Lightstone, Liz, Imperial College London, London, United Kingdom
  • Cairns, Tom, Imperial College Healthcare NHS Trust, London, United Kingdom
  • Pusey, Charles D., Imperial College London, London, United Kingdom
  • Griffith, Megan, Imperial College Healthcare NHS Trust, London, United Kingdom

Rituximab is increasingly used for the treatment of membranous nephropathy (MN), both as first line & for relapsing disease, but there are few published data on long term outcomes.


In this retrospective, observational cohort study we report outcomes of 38 adult patients with biopsy proven MN treated with rituximab between Jan 2008 & Jan 2018. Follow up was for a mean of 4 years (range 1-10). Rituximab, 2 x 1 g doses, was administered at days 0 & 14.


We identified 38 patients, 25 male, median age 57.5yrs (range 23-77). At administration of rituximab, patients were heavily nephrotic with median urinary protein creatinine ratio (uPCR) 851 mg/mmol (range 574-1420) & median eGFR 33 ml/min/1.73m2 (23-59). B cell depletion occurred within 2 weeks of administration; however, 73% of patients were B cell replete at 3 months.
By latest f/up, 27 (71%) patients achieved remission (CR & PR). Median time to PR was 12 mths but CR took longer to achieve, up to 36 mths in some cases. Relapses occurred in 5 (18.5%) responders, of whom 1 died & 1 progressed to ESRD.
There were 11 (29%) non-responders of whom 7 progressed to ESKD.
The eGFR was less than 30ml/min/1.73m2 in 17 patients (44.7%) at the time of rituximab treatment. Whilst 7 of these patients progressed to ESKD, in 10 cases renal function improved or stabilised.
3 patients died during the follow up period one from intracerebral haemorrhage, one from lung malignancy & one from a cardiac event.


Rituximab is effective in treating MN though the time to remission can be prolonged. B cell repletion occurs early in MN however this is not necessarily associated with relapse.
Importantly, response to rituximab can lead to preservation or improvement of renal function even when severely impaired. Such patients may benefit from treatment and should not necessarily be excluded from controlled trials.